jRCT2071230116招募中不适用
A Phase 3 Randomized, Open-label Induction, Double-blind Maintenance, Parallel-group, Multicenter Protocol to Evaluate the Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 120
- 主要终点
- Percentage of Participants with Clinical Remission at Week 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 2age old over 至 17age old under（—）
- 性别
- All
入选标准
- •Weight greater than or equal to (>=) 10 kilogram (kg) at the time of consent for screening
- •A pathology report to support a documented diagnosis of Ulcerative Colitis (UC) must be available in the source documents. There is no maximum duration for which a participant needs to be diagnosed with UC. If the pathology report to support a documented diagnosis of UC is not available in the source documents, the screening endoscopy with biopsies (obtained within 3 weeks before first study intervention administration) needs to support the diagnosis of UC.
- •Moderately to severely active UC, defined by a baseline modified Mayo (without physician's global assessment) score of 5 through 9 inclusive, with a screening Mayo endoscopy subscore >= 2 as determined by a central review of the video of the endoscopy, and a baseline Mayo rectal bleeding subscore >=1
- •Medically stable on the basis of physical examination, medical history, and vital signs, performed at screening. Any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and acknowledged by the investigator
- •Participants must have had an inadequate response and/or intolerance to biologic therapy and/or conventional therapies or be dependent upon corticosteroids
排除标准
- •Have UC limited to the rectum only or to less than (<) 20 centimeter of the colon
- •Presence of a stoma
- •Has had any kind of bowel resection within 6 months or any other intra-abdominal surgery within 3 months of baseline
- •Have severe colitis or have evidence of Crohn's Disease (CD)
结局指标
主要结局
Percentage of Participants with Clinical Remission at Week 56
时间窗: Week 56
Percentage of participants with clinical remission as assessed by modified Mayo score at Week 56 among participants who were induction responders will be reported. Clinical remission per modified Mayo score is defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline.
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
3 期
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric ParticipantsPsoriasisNCT03451851Janssen Research & Development, LLC120
进行中（未招募）
3 期
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeNCT06260163Janssen Research & Development, LLC112
已完成
1 期
A Study of Guselkumab in Participants With Familial Adenomatous PolyposisAdenomatous Polyposis ColiNCT03649971Janssen Research & Development, LLC77
已完成
3 期
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to UstekinumabPsoriasisNCT02203032Janssen Research & Development, LLC872
进行中（未招募）
2 期
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative ColitisUlcerative ColitisNCT04033445Janssen Research & Development, LLC1,064